Nicox holds first ophthalmology Scientific Advisory Board and attends AAO 2013

Nicox holds first ophthalmology Scientific Advisory Board and attends AAO 2013

..................................

November 4, 2013.

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX) today announced it has established a new Scientific Advisory Board (SAB) with international Key Opinions Leaders (KOLs) in the ophthalmology field. The first SAB meeting will be held on November 14, 2013 in New Orleans, Louisiana, United States, with the objective of evaluating the existing data on second generation nitric oxide (NO)-donors and discussing their potential therapeutic use in certain ophthalmic disorders.

Nicox's SAB will be led by Dr. Richard L. Lindstrom, founder and attending surgeon at Minnesota Eye Consultants and Adjunct Clinical Professor Emeritus at the University of Minnesota Department of Ophthalmology. Dr. Lindstrom is an internationally recognized leader in corneal, cataract, refractive and laser surgery.

AAO 2013

Nicox will attend the 2013 Annual Meeting of the American Academy of Ophthalmology (AAO), taking place from November 16 to 18, 2013 in New Orleans, Louisiana, United States. Nicox can be found at booth number 4719. Nicox's US and European operational teams will attend the meeting, as well as several members from the Executive team.

About Dr. Richard L. Lindstrom

Dr Richard L. Lindstrom is Founder and attending surgeon at Minnesota Eye Consultants, Adjunct Clinical Professor Emeritus at the University of Minnesota Department of Ophthalmology. He serves as Associate Director at the Minnesota Lions Eye Bank and as Board Member at the University of Minnesota Foundation. He is also Visiting Professor at UC Irvine's Gavin Herbert Eye Institute and he serves on the Board of Directors of several publicly traded and private companies and on a number of Journal editorial boards.

Dr Lindstrom is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery. He has been at the forefront of ophthalmology's evolutionary changes throughout his career, as a recognized researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon. He holds over 38 patents in ophthalmology and has developed a number of solutions, intraocular lenses and instruments that are used in clinical practices globally.  

...................................

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is latanoprostene bunod, a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com. 

..................................

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés Financiers (AMF) on March 22, 2013 and available on Nicox's website (www.nicox.com) and on the AMF's website (www.amf-france.org).

...................................